Clinical Trials
-
OnabotulinumtoxinA in resistant depression: a randomized trial comparing two facial injection sites (OnaDEP study)
Depression and Anxiety
2024
Caroline Ceolato-Martin, Claire Chevallier-Collins, Jean-Pierre Clément, Eric Charles, Aurélie Lacroix and Danièle Ranoux -
A novel approach to treating post-stroke depression: administration of botulinum toxin A via local facial injection
Frontiers in Neurology
2024
Xiao-Yan Feng, Ting-Ting Shen, Qian-Chang Wu, Jun Wang, Ping Ni, Jing Liu, Xu-Ping Zhou, Hua Hu and Wei-Feng Luo -
Treatment of neuropsychiatric symptoms in Parkinson’s disease with botulinum toxin A: a 12-week randomized, double-blind, placebo-controlled trial
Journal of Geriatric Psychiatry and Neurology
2024
Xiaofeng Zhu, Ming Wei, Lijun Wang, Qiang Tong, Xiu Yang and Qiu Han -
Botulinum Toxin A Therapy for Glabellar Lines Improves Emotional States: Evaluation of 47 Cases without Mental Disorders
Journal of Plastic and Reconstructive Surgery
2023
Hiromi Hanayama, Jun Tada, Hiroto Terashi -
Botulinum toxin A (BoNT/A) for the treatment of depression: A randomized, double-blind, placebo, controlled trial in China
Journal of Affective Disorders
2022
Li et al -
The safety and efficacy of botulinum toxin A on the treatment of depression
Brain and Behavior
2021
Qilin Zhang et al -
Effects of botulinum toxin type a on mood and cognitive function in patients with parkinson’s disease and depression
Am J Transl Res
2021
Changzheng Zhu, Kuijie Wang, Ting Yu, Huaqing -
Botulinum toxin relieves anxiety and depression in patients with hemifacial spasm and blepharospasm
Neuropsychiatric Disease and Treatment
2019
Hongjuan Dong et al -
OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo- controlled trial in adult females
International Clinical Psychopharmacology
2019
Mitchell F. Brin et al -
Emotional proprioception: Treatment of depression with afferent facial feedback
Journal of Psychiatric Research
2016
Eric Finzi, Norman E. Rosenthal -
Efficacy of Botox versus Placebo for Treatment of Patients with Major Depression
Iran J Public Health
2016
Zamanian et al -
Treatment of Major Depressive Disorder Using Botulinum Toxin A: A 24-Week Randomized, Double-Blind, Placebo-Controlled Study
J Clin Psychiatry
2014
Magid et al -
Treatment of depression with onabotulinumtoxinA: A randomized, double-blind, placebo controlled trial
Journal of Psychiatric Research
2013
Eric Finzi, Norman E. Rosenthal -
Facing depression with botulinum toxin: A randomized controlled trial
M. Axel Wollmer et al
2012
Journal of Psychiatric Research -
Botulinum toxin in the treatment of resistant depressive disorder: Comparison of two facial injection sites
Poster (unpublished)
2022
Ceolato et al
Mechanism of Action
-
Amygdala biomarkers of treatment response in major depressive disorder: An fMRI systematic review of SSRI antidepressants
Psychiatry Research: Neuroimaging
2024
Vanessa K. Tassone, Fatemeh Gholamali Nezhad, Ilya Demchenko, Alice Rueda, Venkat Bhat -
Modulation of amygdala activity for emotional faces due to botulinum toxin type A injections that prevent frowning
Scientific Reports
2023
Shauna Stark, Craig Stark, Brian Wong and Mitchell F. Brin -
Neurocircuitry underlying the antidepressant effect of retrograde facial botulinum toxin in mice
Cell and Biosience
2023
Linhui Ni et al -
Botulinum Toxin Treatment for Depression: A New Paradigm for Psychiatry
Toxins
2023
Eric Finzi -
Botox (onabotulinumtoxinA) mechanism of action
Medicine
2022
Mitchell F. Brin, MD and Rami Burstein, PhD -
Postmarketing safety surveillance data reveals antidepressant efects of botulinum toxin across various indications and injection sites
Scientific Reports
2020
Tigran Makunts et al -
Eyelid opening with trigeminal proprioceptive activation regulates a brainstem arousal mechanism
PLOS ONE
2015
Kiyoshi Matsuo, Ryokuya Ban, Yuki Hama and Shunsuke Yuzuriha -
Botulinum toxin-induced facial muscle paralysis affects amygdala responses to the perception of emotional expressions: preliminary findings from an A-B-A design
Biology of Mood and Anxiety Disorders
2014
Kim et al -
Occupancy of serotonin transporters in the amygdala by paroxetine in association with attenuation of left amygdala activation by negative faces in major depressive disorder
Psychiatry Research: Neuroimaging
2014Henricus G. Ruhé, Michiel Koster, Jan Booij, Marcel van Herk, Dick J. Veltman, Aart H. Schene
-
Successful Pharmacologic Treatment of Major Depressive Disorder Attenuates Amygdala Activation to Negative Facial Expressions: A Functional Magnetic Resonance Imaging Study
Journal of Clinical Psychiatry
2011Henricus G. Ruhé, Jan Booij, Dick J. Veltman, Martin C. Michel, Aart H. Schene
-
The Link between Facial Feedback and Neural Activity within Central Circuitries of Emotion—New Insights from Botulinum Toxin-Induced Denervation of Frown Muscles
Cerebral Cortex
2009
Hennelotter et al -
Facial EMG Activity Levels Predict Treatment Outcome in Depression
Psychiatry Research
1984John F. Greden, H. Laurence Price, Nancy Genero, Michael Feinberg, Simon Levine
-
Facial Electromyography as a Predictor of Treatment Outcome in Depression
British Journal of Psychiatry
1981Robert M. Carney, Barry A. Hong, Michael F. O’Connell, Henry Amado
-
Facial Muscle Patterning to Affective Imagery in Depressed and Nondepressed Subjects
Science
1976Gary E. Schwartz, Paul L. Fair, Patricia Salt, Michel R. Mandel, Gerald L. Klerman
Meta-analysis
-
Botulinum toxin for the management of depression: An updated review of the evidence and meta-analysis
Journal of Psychiatric Research
2021
Jara Schulze, Insa Neumann, Michelle Magid, Eric Finzi, Christopher Sinke, M. Axel Wollmer, Tillmann H.C. Krüger -
High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis
Journal of Translational Medicine
2021
Oreste Afatato et al
Animal Models
-
Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson’s Disease
Toxins
2021
Veronica Antipova et al -
Unilateral facial injection of Botulinum neurotoxin A attenuates bilateral trigeminal neuropathic pain and anxiety-like behaviors through inhibition of TLR2-mediated neuroinflammation in mice
Journal of Headache and Pain
2021
Wei-Jia Chen et al -
Antidepressant-Like Action of Single Facial Injection of Botulinum Neurotoxin A is Associated with Augmented 5-HT Levels and BDNF/ERK/CREB Pathways in Mouse Brain
Neuroscience Bulletin
2019
Yang Li et al
Commentary
-
Commentary on Brin et al (2019) clinical trial studying OnabotulinumtoxinA for the treatment of major depressive disorder
Eric Finzi
2022 -
The Need for Alternative Treatments for Depression
Sebastian De Beurs
2022